PitchSend

Investor Presentaiton

R&D investor presentation 10 4 5 Breakfast 6 7 * * M +90 min Lunch +90 min Evening meal mujy *Statistically significant at week 26 +90 min Bedtime 04:00 Breakfast next day PPG: Post-prandial control; FPG: Fasting plasma glucose Change Glargine U100 Icodec in HbA1c Icodec showed improved PPG control, HbA1c, and an increased number of patients reaching target in the phase 2 trial Icodec showed statistically significant post prandial control FPG (mmol/L) Icodec The proportion of patients on icodec reaching HbA1c targets was higher Icodec Glargine U100 Numerical improvement in HbA1c over 26 weeks Glargine U100 Proportion of patients 0.0 100% -0.2 -0.4 -0.6 -0.8 -1.0 -1.2 50% -1.15 25% -1.33 72% 75% 68% 49% 39% -1.4 -1.6 0% 04 8 12 16 20 26 < 7.0% ≤ 6.5% Weeks HbA1c target novo nordisk

View entire presentation